Article
Repressing expression of difficult‐to‐express recombinant proteins during the selection process increases productivity of CHO stable pools
26 May 2023
Abstract excerpt
More than half of licensed therapeutic recombinant proteins (r-proteins) are manufactured using constitutively-expressing, stably-transfected Chinese hamster ovary (CHO) clones. While constitutive CHO expression systems have proven their efficacy for the manufacturing of monoclonal antibodies, many next-generation therapeutics such as cytokines and bispecific antibodies as well as biological targets such as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
